市場調查報告書

間質性膀胱炎 - 市場洞察,流行病學,市場預測(2027年)

Interstitial Cystitis - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 703501
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
間質性膀胱炎 - 市場洞察,流行病學,市場預測(2027年) Interstitial Cystitis - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的間質性膀胱炎(IC)市場,預計從2016年的4兆6,595億8,000萬美元,到2027年擴大為5兆3,727億1,000萬美元規模。

本報告提供間質性膀胱炎的相關調查,疾病概要,患者背景,主要7個國家間質性膀胱炎的患病數、診斷數的預測(今後10年份),上市藥及新藥概要,主要國家市場預測,診斷指南,市場成長要素及障礙,主要企業等資訊總括性彙整。

目錄

第1章 重要考察

第2章 間質性膀胱炎:市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 間質性膀胱炎:疾病背景和概要

  • 簡介
  • 原因
  • 危險因素
  • 徵兆與症狀
  • 病理生理學
  • 生物標記
  • 診斷

第4章 流行病學和患者人口

  • 人口與預測參數
  • 主要的觀察

第5章 主要7個國家的間質性膀胱炎的總患病數

第6章 主要7個國家的間質性膀胱炎的總診斷數

第7章 間質性膀胱炎的流行病學:各國

  • 美國
    • 前提和根據
    • 間質性膀胱炎的總患病數
    • 間質性膀胱炎的總患病數:性別
    • 間質性膀胱炎的總診斷數
    • 間質性膀胱炎的診斷數:各重症度
  • 歐盟5國
  • 德國
    • 間質性膀胱炎的總患病數
    • 間質性膀胱炎的總患病數:性別
    • 間質性膀胱炎的總診斷數
    • 間質性膀胱炎的診斷數:各重症度
  • 法國
    • 間質性膀胱炎的總患病數
    • 間質性膀胱炎的總患病數:性別
    • 間質性膀胱炎的總診斷數
    • 間質性膀胱炎的診斷數:各重症度
  • 義大利
    • 間質性膀胱炎的總患病數
    • 間質性膀胱炎的總患病數:性別
    • 間質性膀胱炎的總診斷數
    • 間質性膀胱炎的診斷數:各重症度
  • 西班牙
    • 間質性膀胱炎的總患病數
    • 間質性膀胱炎的總患病數:性別
    • 間質性膀胱炎的總診斷數
    • 間質性膀胱炎的診斷數:各重症度
  • 英國
    • 間質性膀胱炎的總患病數
    • 間質性膀胱炎的總患病數:性別
    • 間質性膀胱炎的總診斷數
    • 間質性膀胱炎的診斷數:各重症度
  • 日本
    • 間質性膀胱炎的總患病數
    • 間質性膀胱炎的總患病數:性別
    • 間質性膀胱炎的總診斷數
    • 間質性膀胱炎的診斷數:各重症度

第8章 治療流程,現行治療,醫療行為

  • 治療方法
  • 治療流程
    • 美國
    • 日本
    • 歐洲

第9章 未滿足需求

第10章 上市藥

  • Elmiron:Janssen Pharmaceutical
    • 醫藥品概要
    • 作用機制
    • 法規的里程碑
    • 優點和缺點
    • 安全性和有效性
    • 產品簡介
  • RIMSO-50:Mylan Pharmaceutical
    • 作用機制
  • Cystistat:Bioniche Life Sciences Inc
  • Gepan instill:Pohl-Boskamp GmbH
  • Uracyst:Stellar Pharmaceutical
  • Hyacyst:Syner-Med
  • iAluRil:Aspire Pharma

第11章 新藥

  • Key Cross Competition
  • AQX-1125:Aquinox Pharmaceuticals
    • 醫藥品概要
    • 開發活動
    • 臨床開發
    • 安全性和有效性
    • 優點和缺點
    • 產品簡介
  • Mirabegron:Astellas Pharma Global Development Inc.
  • ASP6294:Astellas Pharma Global Development Inc.
  • LP-08:Lipella Pharmaceuticals
  • GRT6010:Grunenthal

第12章 間質性膀胱炎:主要市場分析

  • 主要的觀察
  • 主要7個國家間質性膀胱炎的市場規模

第13章 美國市場預測

  • 市場規模
  • 間質性膀胱炎的市場規模
  • 市場規模:各上市藥
  • 市場規模:各新藥

第14章 歐盟5國市場預測

  • 德國
    • 間質性膀胱炎的市場規模
    • 市場規模:各上市藥
    • 市場規模:各新藥
  • 法國
    • 間質性膀胱炎的市場規模
    • 市場規模:各上市藥
    • 市場規模:各新藥
  • 義大利
    • 間質性膀胱炎的市場規模
    • 市場規模:各上市藥
    • 市場規模:各新藥
  • 西班牙
    • 間質性膀胱炎的市場規模
    • 市場規模:各上市藥
    • 市場規模:各新藥
  • 英國
    • 間質性膀胱炎的市場規模
    • 市場規模:各上市藥
    • 市場規模:各新藥

第15章 日本市場預測

  • 間質性膀胱炎的市場規模
  • 市場規模:各上市藥
  • 市場規模:各新藥

第16章 市場成長要素

第17章 市場障礙

第18章 附錄

  • 調查方法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0065

DelveInsight's "Interstitial Cystitis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Interstitial Cystitis market report provides current treatment practices, emerging drugs, Interstitial Cystitis market share of the individual therapies, current and forecasted Interstitial Cystitis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Interstitial Cystitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Interstitial Cystitis Disease Understanding and Treatment Algorithm

The DelveInsight Interstitial Cystitis market report gives a thorough understanding of the Interstitial Cystitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Interstitial Cystitis.

Treatment

It covers the details of conventional and current medical therapies available in the Interstitial Cystitis market for the treatment of the condition. It also provides Interstitial Cystitis treatment algorithms and guidelines in the United States, Europe, and Japan.

Interstitial Cystitis Epidemiology

The Interstitial Cystitis epidemiology division provide insights about historical and current Interstitial Cystitis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Interstitial Cystitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Interstitial Cystitis Epidemiology

The epidemiology segment also provides the Interstitial Cystitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Interstitial Cystitis Drug Chapters

Drug chapter segment of the Interstitial Cystitis report encloses the detailed analysis of Interstitial Cystitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Interstitial Cystitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Interstitial Cystitis treatment.

Interstitial Cystitis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Interstitial Cystitis treatment.

Interstitial Cystitis Market Outlook

The Interstitial Cystitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Interstitial Cystitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Interstitial Cystitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Interstitial Cystitis market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Interstitial Cystitis market in 7MM.

The United States Market Outlook

This section provides the total Interstitial Cystitis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Interstitial Cystitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Interstitial Cystitis market size and market size by therapies in Japan is also mentioned.

Interstitial Cystitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Interstitial Cystitis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Interstitial Cystitis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Interstitial Cystitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Interstitial Cystitis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Interstitial Cystitis emerging therapies.

Reimbursement Scenario in Interstitial Cystitis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Interstitial Cystitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Interstitial Cystitis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Interstitial Cystitis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Interstitial Cystitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Interstitial Cystitis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Interstitial Cystitis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Interstitial Cystitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Interstitial Cystitis market

Report Highlights

  • In the coming years, Interstitial Cystitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Cystitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Interstitial Cystitis. Launch of emerging therapies will significantly impact the Interstitial Cystitis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Interstitial Cystitis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Interstitial Cystitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Interstitial Cystitis Pipeline Analysis
  • Interstitial Cystitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Interstitial Cystitis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Interstitial Cystitis Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Interstitial Cystitis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Interstitial Cystitis market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Interstitial Cystitis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Interstitial Cystitis market size during the forecast period (2017-2030)?
  • At what CAGR, the Interstitial Cystitis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Interstitial Cystitis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Interstitial Cystitis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Interstitial Cystitis?
  • What is the historical Interstitial Cystitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Interstitial Cystitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Interstitial Cystitis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Interstitial Cystitis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Interstitial Cystitis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Interstitial Cystitis in the USA, Europe, and Japan?
  • What are the Interstitial Cystitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Interstitial Cystitis?
  • How many therapies are developed by each company for Interstitial Cystitis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Interstitial Cystitis treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Interstitial Cystitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Interstitial Cystitis and their status?
  • What are the key designations that have been granted for the emerging therapies for Interstitial Cystitis?
  • What are the global historical and forecasted market of Interstitial Cystitis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Interstitial Cystitis market
  • To understand the future market competition in the Interstitial Cystitis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Interstitial Cystitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Interstitial Cystitis market
  • To understand the future market competition in the Interstitial Cystitis market

Table of Contents

1. Key Insights

2. Executive Summary of Interstitial Cystitis

3. Competitive Intelligence Analysis for Interstitial Cystitis

4. Interstitial Cystitis: Market Overview at a Glance

  • 4.1. Interstitial Cystitis Total Market Share (%) Distribution in 2017
  • 4.2. Interstitial Cystitis Total Market Share (%) Distribution in 2030

5. Interstitial Cystitis: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Interstitial Cystitis Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Interstitial Cystitis Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Interstitial Cystitis Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Interstitial Cystitis Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Interstitial Cystitis Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Interstitial Cystitis Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Interstitial Cystitis Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Interstitial Cystitis Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Interstitial Cystitis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Interstitial Cystitis Treatment and Management
  • 8.2. Interstitial Cystitis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Interstitial Cystitis Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Interstitial Cystitis: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Interstitial Cystitis Market Size in 7MM
  • 13.3. Interstitial Cystitis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Interstitial Cystitis Total Market Size in the United States
    • 15.1.2. Interstitial Cystitis Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Interstitial Cystitis Total Market Size in Germany
    • 15.3.2. Interstitial Cystitis Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Interstitial Cystitis Total Market Size in France
    • 15.4.2. Interstitial Cystitis Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Interstitial Cystitis Total Market Size in Italy
    • 15.5.2. Interstitial Cystitis Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Interstitial Cystitis Total Market Size in Spain
    • 15.6.2. Interstitial Cystitis Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Interstitial Cystitis Total Market Size in the United Kingdom
    • 15.7.2. Interstitial Cystitis Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Interstitial Cystitis Total Market Size in Japan
    • 15.8.3. Interstitial Cystitis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Interstitial Cystitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Interstitial Cystitis Epidemiology (2017-2030)
  • Table 2 : 7MM Interstitial Cystitis Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Interstitial Cystitis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Interstitial Cystitis Epidemiology in Germany (2017-2030)
  • Table 6 : Interstitial Cystitis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Interstitial Cystitis Epidemiology in France (2017-2030)
  • Table 8 : Interstitial Cystitis Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Interstitial Cystitis Epidemiology in Italy (2017-2030)
  • Table 10 : Interstitial Cystitis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Interstitial Cystitis Epidemiology in Spain (2017-2030)
  • Table 12 : Interstitial Cystitis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Interstitial Cystitis Epidemiology in the UK (2017-2030)
  • Table 14 : Interstitial Cystitis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Interstitial Cystitis Epidemiology in Japan (2017-2030)
  • Table 16 : Interstitial Cystitis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Interstitial Cystitis Epidemiology (2017-2030)
  • Figure 2 : 7MM Interstitial Cystitis Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Interstitial Cystitis Epidemiology in the United States (2017-2030)
  • Figure 4 : Interstitial Cystitis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Interstitial Cystitis Epidemiology in Germany (2017-2030)
  • Figure 6 : Interstitial Cystitis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Interstitial Cystitis Epidemiology in France (2017-2030)
  • Figure 8 : Interstitial Cystitis Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Interstitial Cystitis Epidemiology in Italy (2017-2030)
  • Figure 10 : Interstitial Cystitis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Interstitial Cystitis Epidemiology in Spain (2017-2030)
  • Figure 12 : Interstitial Cystitis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Interstitial Cystitis Epidemiology in the UK (2017-2030)
  • Figure 14 : Interstitial Cystitis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Interstitial Cystitis Epidemiology in Japan (2017-2030)
  • Figure 16 : Interstitial Cystitis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)